+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a single intravitreal injection of 4D-150 compared to aflibercept in adults with neovascular age-related macular degeneration nAMD. This Phase 3 randomized, double-masked trial includes a primary global cohort with completed enrollment and an ongoing Japan cohort. The study aims to understand visual acuity changes and treatment needs over time in this patient population. Participants are randomly assigned to receive either one dose of 4D-150 administered as a single intravitreal injection on Day 1 or aflibercept injections at scheduled visits. The study follows participants for up to 104 weeks to assess the need for additional aflibercept injections after the initial treatment. The trial includes safety and efficacy monitoring with comparisons between the study drug and the active comparator. During the trial, participants will undergo regular eye exams including measurements of best corrected visual acuity BCVA at 52 weeks and up to 104 weeks. Central subfield thickness and other anatomical features will be monitored using imaging techniques such as fluorescein angiography and optical coherence tomography. Researchers will track injection frequency, visual function, and eye health. The total participation duration may span over two years with ongoing assessments to evaluate treatment outcomes and safety.

Age: 50Years +All GendersPhase 3
126 locations